DC
INO icon

Davenport & Co’s Inovio Pharmaceuticals INO Stock Holding History

Davenport & Co’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,529
Closed -$301K – 737
2019
Q3 		$301K Hold
8,529
– – ﹤0.01% 558
2019
Q2 		$301K Buy
+8,529
New +$339K ﹤0.01% 561

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Davenport & Co's INO Position: Q4 2019 in Review

Davenport & Co sold out of Inovio Pharmaceuticals (INO) in Q4 2019, closing a stake of 8,529 shares — an estimated $301K sold.

Davenport & Co first reported a position in INO in Q2 2019 and held it in 2 quarters. The position peaked at $301K in Q3 2019. 106 funds tracked by Wall St. Rank hold INO as of Q4 2019.

  • Davenport & Co reported no remaining Inovio Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Davenport & Co sold 8,529 Inovio Pharmaceuticals shares in Q4 2019, an estimated $301K.
  • Davenport & Co first reported a position in Inovio Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Davenport & Co's Inovio Pharmaceuticals position peaked at $301K in Q3 2019.
  • 106 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2019.

Based on Davenport & Co's 13F filing for Q4 2019, filed 22 Jan 2020.